---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121088"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:25:22.720982+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Beam Therapeutics discusses Q3 results and ASH abstracts on investor call

## Summary
- Investor presentation covered Q3 financial results, but no specific figures provided in filing.
- Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.
- Company reiterated sickle cell disease strategy and provided business update.

## SEC filing metadata
- accession: 0000950170-24-121088
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/0000950170-24-121088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/beam-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121088
- JSON: https://secwatch.observer/filing/0000950170-24-121088.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.